[Lysophosphatidic acid in ovarian cancer patients].
OBJECTIVE
To compare plasma lysophosphatidic acid (LPA) level in ovarian cancer patients and women without ovarian pathology.


METHODS
Prospective study.


METHODS
Department of Gynecology and Obstetrics, University Hospital, Hradec Králové.


METHODS
The method for LPA level analyze with its specification by capillary electrophoresis using indirect ultraviolet detection has been implementated. Since the beginning of this project venous blood samples from 103 patients (60 patients with ovarian cancer, 43 patients without ovarian pathology) have been obtained.


RESULTS
Plasma LPA levels were elevated in ovarian cancer patients (sigma LPA Med 19.9 micromol/l, Range 4.5-42.7 micromol/l). Patients without ovarian pathology (n=35) (sigma LPA Med 2.6 micromol/l, Range 0.9-22.9 micromol/l, P<0,001) had statistically significant lower plasma LPA level compared with ovarian cancer patients.


CONCLUSIONS
Lysophosphatidic acid appears useful as diagnostic marker of ovarian cancer.
Sedlákova
I
I
Department of Gynecology and Obstetrics, University Hospital, Hradec Králové.
Vávrová
J
J
Tosner
J
J
Hanousek
L
L
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D002277:Carcinoma / Q000097:blood / Q000175:diagnosis*; D005260:Female; D006801:Humans; D008246:Lysophospholipids / Q000097:blood*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood / Q000175:diagnosis*
D014408:Biomarkers, Tumor; D008246:Lysophospholipids; C032881:lysophosphatidic acid